Naloxegol: Treatment for Opioid-Induced Constipation in Chronic Non–Cancer Pain

Annals of Pharmacotherapy

Volumn 49, Issue 3, 2015, Pages 360-365

  Leonard, James ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

naloxegol; new drugs; opioid induced constipation; reviews

Indexed keywords

LAXATIVE; NALOXEGOL; NARCOTIC ANALGESIC AGENT; PLACEBO; MACROGOL DERIVATIVE; MORPHINAN DERIVATIVE; NARCOTIC ANTAGONIST;

ABDOMINAL PAIN; CHRONIC PAIN; CLINICAL TRIAL (TOPIC); CONSTIPATION; DEFECATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULARY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FLATULENCE; HUMAN; NAUSEA; OPIOID INDUCED CONSTIPATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; REVIEW; TREATMENT FAILURE; ADULT; AGED; CHEMICALLY INDUCED; FEMALE; MALE; METABOLISM;

ADULT; AGED; ANALGESICS, OPIOID; CHRONIC PAIN; CONSTIPATION; FEMALE; HUMANS; LAXATIVES; MALE; MORPHINANS; NARCOTIC ANTAGONISTS; POLYETHYLENE GLYCOLS;

EID: 84923850811     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014560191     Document Type: Review

References (26)

1. Medicine Use and Shifting Costs of Healthcare: A Review of the Use of Medicines in the United States in 2013. Parsippany, NJ: IMS Institute for Healthcare Informatics; 2014:
2. Manchikanti L,Abdi S,Atluri S, et al.American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2. Guidance.Pain Physician. 2012;15:S67-S116
3. Camilleri M,Drossman DA,Becker G,Webster LR,Davies AN,Mawe GM.Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation.Neurogastroenterol Motil. 2014;26:1386-1395
4. Coyne KS,LoCasale RJ,Datto CJ,Sexton CC,Yeomans K,Tack J.Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review.Clinicoecon Outcomes Res. 2014;6:269-281
5. Ruston T,Hunter K,Cummings G,Lazarescu A.Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systemic review.Can Oncol Nurs J. 2014;23:236-246
6. Eldon MA,Song D,Neumann TA, et al.NKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone: Demonstration of selective peripheral opioid antagonism after oral administration in preclinical models.Poster presented at: the American Academy of Pain Management 18th Annual Clinical Meeting; Las Vegas, NV;.
7. Bui K,She F,Sostek M.The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol.J Clin Pharmacol. 2014;:
8. Neumann TA,van Paaschen H,Marcantonio A,Song D,Morrison P,Eldon MA.Evaluation of single oral doses of NKTR-118 (PEG-Naloxol) as an oral peripheral opioid antagonist in healthy male subjects [abstract].J Clin Pharmacol. 2007 1210;47:
9. Neumann TA,van Paaschen H,Marcantonio A,Song D,Kugler AR,Eldon MA.Evaluation of PEG-Naloxol (NKTR-118) as an oral peripheral opioid antagonist in healthy male subjects: a double-blind, placebo-controlled, dose escalation crossover study.Poster presented at: 36th Annual American College of Clinical Pharmacology Meeting; September 9-11, 2007 San Francisco, CA;.
10. Webster L,Dhar S,Eldon M,Masuoka L,Lappalainen J,Sostek M.A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.Pain. 2013;154:1542-1550
11. Gottfridsson C,Carlson G,Lappalainen J,Sostek M.Evaluation of the effect of naloxegol on cardiac repolarization: a randomized, placebo-and positive-controlled crossover thorough QT/QTc study in healthy volunteers.Clin Ther. 2013;35:1876-1883
12. Odinecs A,Song Y,Harite S,Lee MG,Kugler AR,Eldon MA.NKTR-118, an oral peripheral opioid antagonist, has low potential for drug-drug interactions [abstract].J Clin Pharmacol. 2009 1123;49:
13. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014:
14. Bui K,She F,Sostek M.The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol.J Clin Pharmacol. 2014;:
15. Chey WD,Webster L,Sostek M,Lappalainen J,Barker PN,Tack J.Naloxegol for opioid-induced constipation in patients with noncancer pain.N Engl J Med. 2014;370:2387-2396
16. Webster L,Chey WD,Tack J,Lappalainen J,Diva U,Sostek M.Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.Aliment Pharmacol Ther. 2014;40:771-779
17. Food and Drug Administration, Center for Drug Evaluation and Research. Opioid antagonists for the treatment of opioid induced constipation. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anestheticandanalgesicdrugproductsadvisorycommittee/ucm400205.pdf. Accessed August 20, 2014.
18. Lexington, MA: Cubist Pharmaceuticals, Inc; 2013:
19. Food and Drug Administration. Summary minutes of the Anesthetic and Analgesic Drug Products Advisory Committee Meeting:June11-12, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM407429.pdf. Accessed September 16, 2014.
20. AstraZeneca. Naloxegol NDA: 204-760. Briefing document for the Anesthetic and Analgesic Drug Products Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM400209.pdf. Accessed August 20, 2014.
21. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2013:
22. Raleigh, NC: Salix Pharmaceuticals, Inc; 2014:
23. FDA approves MOVANTIK (naloxegol) tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. http://ir.nektar.com/releasedetail.cfm?ReleaseID=871146. Accessed September 16, 2014. 25.
24. US Drug Enforcement Administration. Drug schedules. http://www.justice.gov/dea/druginfo/ds.shtml. Accessed October 14, 2014.
25. Drug Enforcement Administration. Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule iii to schedule ii. https://www.federalregister.gov/articles/2014/08/22/2014-19922/schedules-of-controlled-substances-rescheduling-of-hydrocodone-combination-products-from-schedule. Accessed September 16, 2014.
26. Drug Enforcement Agency: Office of Diversion Control. Title 21 United States Code (USC) Controlled Substances Act. Subchapter I: control and enforcement. Section 802. http://www.deadiversion.usdoj.gov/21cfr/21usc/802.htm. Accessed October 14, 2014.